Skip to main content
    M

    Mediwound Ltd (MDWD)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $13.55
    +0.65 (+5.04%)

    Market Cap: $185.63M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Mediwound Ltd (MDWD) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Mediwound (MDWD) trades at 17.6x sales and 5.6x book value. Its P/S of 17.6x is above its 5-year median of 7.3x. Its forward P/E is 35.0x.

    Current Multiples

    MultipleValue
    P/E (trailing)N/A
    Forward P/E35.0x
    Price to sales17.6x
    Price to book5.6x
    PEGN/A
    FCF yield-18.4%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/S is 122.8% above 7.9x and its P/B is 27.3% below 7.7x.

    MultipleCurrent5-year median10-year median
    P/S17.6x7.3x7.9x
    P/B5.6x5.3x7.7x
    Medians of month-end values through Oct 2026: 50 to 60 months (5-year) and 102 to 120 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/S ranged from 2.6x in 2022 to 64.2x in 2016.

    Year endPriceP/EP/SP/B
    2025$18.46N/A12.1x5.4x
    2024$17.80N/A8.7x6.2x
    2023$10.17N/A4.9x3.0x
    2022$13.49N/A2.6x7.8x
    2021$16.52N/A2.7xN/A
    2020$25.89N/A4.6x13.8x
    2019$21.6938.7x2.6x5.6x
    2018$28.41N/A32.4x12.3x
    2017$31.14N/A41.0x12.5x
    2016$32.04N/A64.2x12.9x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About MDWD

    What is MDWD's forward P/E ratio?

    Mediwound has a forward P/E ratio of 35.0x.

    Is MDWD stock overvalued?

    GNG's valuation label for MDWD is Overvalued.

    What is MDWD's price to sales ratio?

    Mediwound has a price to sales ratio of 17.6x.